Jipan Xie

Education

Ph.D., health policy and administration, the University of North Carolina at Chapel Hill; M.D., Peking Union Medical College

Summary of Experience

Dr. Xie is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluations, health technology assessments in both the US and global markets, and comparative outcomes research using clinical trial and real-world data. She has worked in a variety of disease areas, such as mental health, oncology, cardiovascular and other chronic diseases, as well as infectious diseases. Her work has been widely published in leading clinical, economic, and managed care journals, including Circulation, Stroke, PharmacoEconomics, Value in Health, and American Journal of Managed Care. Dr. Xie has extensive experience in emerging markets, particularly in China. Her work in this area includes outcomes research using high-quality EMR data, economic evaluations, market access of oncology drugs, burden of illness based on claims and surveys, and the China National Stroke Registry design and revision of the treatment guidelines for hypertension and diabetes. She was a coeditor of PharmacoEconomics journal's special issue on health care in China. She also serves as an adjunct professor at Shanghai Jiao Tong University School of Public Health. Prior to joining Analysis Group, Dr. Xie was a health service researcher at the Centers for Disease Control and Prevention, leading the health services and outcomes research in the Division for Heart Disease and Stroke Prevention.

Selected Publishing

• Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States

  Current Medical Research and Opinion. Apr 2018;34(4):585-592
  2018

  Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R

  Health Care
• Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States

  Journal of Medical Economics. Mar 12 2018:1-10
  2018

  Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K

  Health Care
• Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis

  Clinical Therapeutics. Apr 2018;40(4):628-639 e623
  2018

  Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA

• Policy Considerations: Ex-US Payers and Regulators

  Decision Making in a World of Comparative Effectiveness Research
  2017

  Xie J, Chalkidou K, Kamae I, Dittrich R, Mahbub R, Vasan A, Metallo C

   

  Epidemiology & Biostatistics, Health Care
• Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer

  Expert Opinion on Pharmacotherapy. Aug 2017;18(12):1167-1178
  2017

  Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH

  Health Care
• Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014

  Journal of the American Academy of Dermatology. Jul 2017;77(1):55-62 e53
  2017

  Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB

  Health Care
• Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.

  Advances in Therapy. Dec 2017;34(12):2566-2584
  2017

  Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA

  Health Care
• Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors

  American Health and Drug Benefits. November 2017;10(8):408-415
  2017

  Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB 

• Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison

  European Child and Adolescent Psychiatry. Aug 2017;26(8):875-897
  2017

  Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V

  Health Care
• First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

  Current Medical Research and Opinion. Dec 2017;33(12):2137-2143
  2017

  Tang DH, Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V

  Health Care
• Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites

  Clinical Therapeutics, 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08
  2016

  Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ

• Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

  Journal of Blood Medicine, 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23
  2016

  Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J

• Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension

  Curr Med Res Opin. 2014 Apr;30(4):637-43
  2014

  Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ

  Health Care
• A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy

  Eur J Gastroenterol Hepatol. 2013 Jun; 25(6):739-47
  2013

  Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

  Health Care
• Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States

  J Med Econ. 2013; 16(2):278-88
  2013

  Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

  Health Care
• Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

  UroToday.com, Beyond the Abstract, July 2012
  2012

  Xie J

  Health Care
• Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of ADHD

  Pharmacoeconomics. 2012 Aug 1;30(8):e1-15
  2012

  Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ

  Health Care, Strategy, Policy & Analytics
• Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

  J Med Econ. 2012; 15(6):1078-87
  2012

  Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

  Health Care
• Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer

  Journal of Medical Economics, 1-26, November 16, 2012
  2012

  Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M

  Health Care, Intellectual Property, Strategy, Policy & Analytics
• Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events

  Journal of Medical Economics; December 5, 2012 [Letter to the Editor]
  2012

  Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M

  Health Care
• The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate-severe psoriasis

  JAAD. 2011 May 24
  2011

  Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM

  Health Care
• Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

  Journal of Managed Care Pharmacy. 2011;17(8):621-34
  2011

  Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW

  Health Care
• Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement

  Curr Med Res Opin. 2010 Sep;26(9):2203-12
  2010

  Chang J, Yang W, Fellers T, Kahler K, Orloff J,  Xie J, Tsaneva M, Yu A,  Wu EQ

  Epidemiology & Biostatistics, Health Care
• Systematic review: the costs of ulcerative colitis in Western countries

  Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
  2010

  Cohen R, Yu AP,  Wu EQ,  Xie J, Mulani P, Chao J

  Epidemiology & Biostatistics, Health Care
• Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram

  J Med Econ. 2010 Sep 29. [Epub ahead of print]
  2010

  Yu A,  Xie J, Bensimon A, Parikh K,  Wu E, Ben-Hamadi R, Blum S, Haim Erder

  Health Care
• Economic burden of psoriasis compared to the general population and stratified by disease severity

  Curr Med Res Opin. 2009 Oct;25(10):2429-38
  2009

  Yu AP, Tang J,  Xie J,  Wu EQ, Gupta SR, Bao Y, Mulani PM

  Epidemiology & Biostatistics, Health Care
• Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States

  Stroke, 2006 Oct;37(10):2567-72
  2006

  Xie J, Wu E, Zheng Z, Croft J, Greenlund K, Mensah G, Labarthe D

  Epidemiology & Biostatistics, Health Care

News

• December 11, 2018

  Vice President Jipan Xie Discusses Importance of Evidence Based on Surrogate Outcomes for Drug Reimbursement Approval

  Health Care
• November 02, 2017

  ISPOR Annual European Congress to Feature New Outcomes Research from Analysis Group’s Health Care Practice

  Health Care,
• August 15, 2016

  Analysis Group to Present New Outcomes Research at ISPOR Asia-Pacific

  Health Care,